Lercanidipino Recordati

Lercanidipine hydrochloride, the active ingredient in Lercanidipino Recordati, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to treat hypertension in adult patients by relaxing vascular smooth muscle and lowering peripheral resistance.

GNH USA supplies Lercanidipino Recordati as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure by relaxing peripheral arteries.

Lercanidipine may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain often occurring early in therapy. - Flushing: transient warmth and reddening of the skin, especially on the face. - Peripheral edema: swelling of the ankles or feet due to fluid accumulation.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause dizziness or fainting. - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Liver enzyme elevation: abnormal hepatic function tests indicating possible liver involvement.

Before initiating therapy, clinicians should consider several safety factors. - Dose adjustment: consider lower starting doses in elderly patients. - Renal impairment: monitor kidney function and adjust if necessary. - Hepatic impairment: use with caution and observe liver enzymes. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Pregnancy: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lercanidipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can elevate drug concentration and enhance hypotensive effect. - Other calcium channel blockers: additive vasodilatory action may cause excessive hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect and lead to electrolyte imbalance. - Beta‑blockers: combined effect on blood pressure warrants close monitoring. - ACE inhibitors/ARBs: monitor renal function and potassium levels when used together.